ResMed Inc. $RMD Stock Holdings Lifted by National Pension Service

National Pension Service lifted its position in ResMed Inc. (NYSE:RMD) by 1.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 243,543 shares of the medical equipment provider’s stock after buying an additional 2,709 shares during the quarter. National Pension Service’s holdings in ResMed were worth $58,662,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in RMD. Terra Nova Asset Management LLC boosted its holdings in shares of ResMed by 0.6% during the third quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider’s stock worth $2,136,000 after purchasing an additional 46 shares during the period. IMA Advisory Services Inc. boosted its holdings in shares of ResMed by 52.7% during the third quarter. IMA Advisory Services Inc. now owns 139 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 48 shares during the period. Occidental Asset Management LLC boosted its holdings in shares of ResMed by 3.0% during the fourth quarter. Occidental Asset Management LLC now owns 1,699 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 49 shares during the period. Wedmont Private Capital boosted its holdings in shares of ResMed by 2.7% during the fourth quarter. Wedmont Private Capital now owns 2,183 shares of the medical equipment provider’s stock worth $542,000 after purchasing an additional 57 shares during the period. Finally, New Wave Wealth Advisors LLC boosted its holdings in shares of ResMed by 3.0% during the fourth quarter. New Wave Wealth Advisors LLC now owns 1,956 shares of the medical equipment provider’s stock worth $471,000 after purchasing an additional 57 shares during the period. 54.98% of the stock is owned by hedge funds and other institutional investors.

ResMed Price Performance

NYSE RMD opened at $190.58 on Friday. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $27.64 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 1.21 and a beta of 0.84. The company has a 50 day moving average price of $216.93 and a two-hundred day moving average price of $239.34. ResMed Inc. has a 12-month low of $190.38 and a 12-month high of $293.81.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. The firm had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The company’s revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.37 earnings per share. As a group, equities analysts predict that ResMed Inc. will post 11.13 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th will be paid a $0.60 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a yield of 1.3%. ResMed’s payout ratio is 23.14%.

Analyst Ratings Changes

Several analysts recently commented on RMD shares. JPMorgan Chase & Co. started coverage on shares of ResMed in a report on Wednesday, April 15th. They set an “overweight” rating for the company. KeyCorp decreased their price target on shares of ResMed from $302.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, April 27th. Royal Bank Of Canada raised their price target on shares of ResMed from $314.00 to $321.00 and gave the stock an “outperform” rating in a report on Friday, May 1st. Weiss Ratings cut shares of ResMed from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 22nd. Finally, Wall Street Zen cut shares of ResMed from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $286.18.

Insider Buying and Selling

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $207.82, for a total transaction of $1,037,229.62. Following the completion of the sale, the chief executive officer owned 466,223 shares of the company’s stock, valued at $96,890,463.86. This trade represents a 1.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,973 shares of company stock valued at $4,386,031 over the last quarter. Corporate insiders own 0.65% of the company’s stock.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.